Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
13 stopped studies mapped to Mucosal Melanoma and descendants · 92% state a reason
Over the 13 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT07076550 | A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408… | Phase 1 | terminated | Jul 22, 2025 | Alpha-9 Oncology USA Inc. | Due to a strategic decision to re-prioritize the sponsor's existing portfolio. | Sponsor / business decision |
| NCT03178123 | The Study of JS001 Compared to High-Dose Interferon In Patients With Mucosal Melanoma… | Phase 2 | terminated | Jun 6, 2017 | Shanghai Junshi Bioscience Co., Ltd. | The study strategy was adjusted, and the company decided to terminate the study early | Sponsor / business decision |
| NCT07614828 | Exploratory Clinical Study of Neoadjuvant Immunotherapy Combined With Chemotherapy in… | Phase 2 | withdrawn | May 29, 2026 | Eye & ENT Hospital of Fudan University | no participants enrolled | Enrollment / accrual |
| NCT05341349 | Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the… | Phase 1 | terminated | Apr 22, 2022 | Emory University | Slow accrual | Enrollment / accrual |
| NCT03865212 | Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma | Phase 1 | terminated | Mar 6, 2019 | Mayo Clinic | Lack of funding; lack of objective response | Funding |
| NCT04830124 | Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With…(ARTISTRY-6) | Phase 2 | terminated | Apr 2, 2021 | Mural Oncology, Inc | Study terminated due to business and strategic decision. | Sponsor / business decision |
| NCT05436990 | Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Acral and Mucosal… | Phase 2 | terminated | Jun 29, 2022 | Yonsei University | According to the protocol criteria, during the Phase 1 analysis, the registered participants'… | Other (stated, no rule matched) |
| NCT05545969 | Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma(Neo PeLeMM) | Phase 2 | withdrawn | Sep 19, 2022 | Melanoma Institute Australia | Insufficient funding | Funding |
| NCT02978443 | A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab… | Phase 2 | terminated | Dec 1, 2016 | Georgetown University | Lack of Enrollment | Enrollment / accrual |
| NCT05482074 | Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2 | Phase 2 | withdrawn | Aug 1, 2022 | Dana-Farber Cancer Institute | Principal Investigator left the institute | Investigator |
| NCT02748564 | Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma | Phase 2 | terminated | Apr 22, 2016 | Rutgers, The State University of New Jersey | Study Complete | Other (stated, no rule matched) |
| NCT03220009 | Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in… | Phase 2 | withdrawn | Jul 18, 2017 | National Cancer Institute (NCI) | The study was never approved by CTEP neither was it ever activated | Other (stated, no rule matched) |
| NCT01166126 | Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV | Phase 2 | terminated | Jul 20, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Aug 31, 2026source: clinicaltrials